ACADIA PHARMACEUTICALS INC. Lease, Cost
ACADIA PHARMACEUTICALS INC. (ACAD) reported Lease, Cost of $4.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. lease, cost for the quarter ending 2026-06-30 was $4.45M, a 35.82% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. lease, cost for the quarter ending 2026-03-31 was $3.54M, a 2.70% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. lease, cost for the quarter ending 2025-12-31 was $2.95M, a 0.64% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. lease, cost for the quarter ending 2025-09-30 was $2.94M, a 41.27% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. lease, cost for fiscal 2025 was $12.61M, a 25.94% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. lease, cost for fiscal 2024 was $10.01M, a 2.32% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. lease, cost for fiscal 2023 was $10.25M, a 26.62% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. lease, cost for fiscal 2022 was $8.10M, a 8.78% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.45M 10-Q · filed 2026-08-05 | $7.99M 10-Q · filed 2026-08-05 | $10.94M derived: sum of 3 quarters · filed 2026-08-05 | $13.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.54M 10-Q · filed 2026-05-07 | $6.49M derived: sum of 2 quarters · filed 2026-05-07 | $9.43M derived: sum of 3 quarters · filed 2026-05-07 | $12.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.88M derived: sum of 2 quarters · filed 2026-02-26 | $9.16M derived: sum of 3 quarters · filed 2026-08-05 | $12.61M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.94M 10-Q · filed 2025-11-06 | $6.21M derived: sum of 2 quarters · filed 2026-08-05 | $9.66M 10-Q · filed 2025-11-06 | $12.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.27M 10-Q · filed 2026-08-05 | $6.72M 10-Q · filed 2026-08-05 | $9.69M derived: sum of 3 quarters · filed 2026-08-05 | $11.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.45M 10-Q · filed 2026-05-07 | $6.42M derived: sum of 2 quarters · filed 2026-05-07 | $8.49M derived: sum of 3 quarters · filed 2026-05-07 | $10.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.04M derived: sum of 2 quarters · filed 2026-02-26 | $7.49M derived: sum of 3 quarters · filed 2026-02-26 | $10.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.08M 10-Q · filed 2025-11-06 | $4.52M derived: sum of 2 quarters · filed 2025-11-06 | $7.05M 10-Q · filed 2025-11-06 | $9.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.44M 10-Q · filed 2025-08-07 | $4.97M 10-Q · filed 2025-08-07 | $7.59M derived: sum of 3 quarters · filed 2026-02-26 | $10.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.52M 10-Q · filed 2025-05-08 | $5.15M derived: sum of 2 quarters · filed 2026-02-26 | $7.85M derived: sum of 3 quarters · filed 2026-02-26 | $10.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.33M derived: sum of 2 quarters · filed 2026-02-26 | $8.07M derived: sum of 3 quarters · filed 2026-02-26 | $10.25M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.71M 10-Q · filed 2024-11-07 | $5.45M derived: sum of 2 quarters · filed 2024-11-07 | $7.63M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $2.74M 10-Q · filed 2024-08-07 | $4.92M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $2.18M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $8.10M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $8.87M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |